Genelux Announces Exclusive Out-Licensing Agreement with ELIAS Animal Health for V-VET1, a Proprietary Oncolytic Vaccinia Virus Treatment for Pets with Various Cancers

WESTLAKE VILLAGE, Calif.: WESTLAKE VILLAGE, Calif., Nov. 18, 2021 /PRNewswire/ -- Genelux Corporation, a clinical-stage immunotherapy company, today announced an exclusive worldwide licensing agreement for V-VET1, its clinical stage animal health product candidate, with ELIAS Animal Health, a biotechnology company advancing its novel T cell-based immunotherapies for the treatment of...

Click to view original post